Titan Pharmaceuticals shareholders approve private placement issuance >20% stock and director election at annual meeting

TITAN PHARMACEUTICALS INC

Shareholders elected all five director nominees: Ben-Tzvi, Chiam, Flores Garcia, Mokhtar, Loh; each received >300K votes for.
Proposal to approve issuance of >20% of common stock in private placement for Nasdaq compliance passed with 280,752 votes for.
Amendment to 2015 Omnibus Equity Incentive Plan to increase authorized shares and extend term by 5 years approved (281,463 for).
Advisory say-on-pay frequency set to every 2 years after receiving 255,240 votes; board adopted that frequency.
Ratification of Enrome LLP as independent auditor for FY 2025 approved with 476,200 votes for.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.